{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-23-000056","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.509084+00:00","generated_at":"2026-06-12T02:02:47.870256+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Recursion predicts protein targets for 36B compounds; Q2 net loss $76.7M, revenue $11M","bullets":["Predicted protein targets for ~36B compounds in Enamine REAL Space, evaluating 2.8 quadrillion target-compound pairs using NVIDIA DGX Cloud.","Q2 2023 revenue $11.0M (up from $7.7M); net loss $76.7M (up from $65.6M); cash $405.9M, excluding $50M NVIDIA investment.","Received $50M investment from NVIDIA; collaboration to build AI foundation models for drug discovery.","Appointed David Mauro as CMO and Nathan Hatfield as Chief Legal Officer.","First Phase 1 data readout for REC-3964 expected in Q3 2023; multiple pipeline catalysts through 2024-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-23-000056","json":"https://secwatch.observer/filing/0001601830-23-000056.json","markdown":"https://secwatch.observer/filing/0001601830-23-000056.md","text":"https://secwatch.observer/filing/0001601830-23-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/0001601830-23-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/rxrx-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:02:47.870256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"455f3a8a661811941e10c40d188d63dda4358524","claim":"RECURSION PHARMACEUTICALS, INC. reported financial results for second quarter ending June 30, 2023.","evidence_excerpt":"Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/0001601830-23-000056-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ending June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}